Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Noven/Banner Receive FDA “Approvable” Letter For Stavzor

This article was originally published in The Pink Sheet Daily

Executive Summary

Data requested by the agency to complete the 505(b)(2) NDA is all “non-clinical,” Noven says.

You may also be interested in...



Noven's Stavzor Final Approval Anticipated In Mid-2008 After FDA Offers “Tentative Approval”

Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.

Noven's Stavzor Final Approval Anticipated In Mid-2008 After FDA Offers “Tentative Approval”

Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.

Noven Gains Phase III Vasomotor Symptoms Candidate With JDS Acquisition

Miami firm predicts four potential new product launches in four years based on specialty pharma JDS’ pipeline.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel